Eli Lilly and Company (NYSE:LLY) issued its earnings results on Tuesday. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02, Bloomberg Earnings reports. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.88 earnings per share. Eli Lilly and updated its FY17 guidance to $4.15-4.25 EPS.

Eli Lilly and (LLY) opened at 87.18 on Tuesday. The firm has a market cap of $91.97 billion, a P/E ratio of 37.72 and a beta of 0.34. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $89.09. The company has a 50-day moving average price of $84.58 and a 200-day moving average price of $82.25.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 990,000 shares of company stock valued at $82,949,650 in the last quarter. 0.20% of the stock is owned by corporate insiders.

LLY has been the subject of a number of research analyst reports. Leerink Swann lifted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Monday, October 16th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Barclays PLC lifted their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Finally, Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $89.12.

WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/24/eli-lilly-and-company-lly-issues-earnings-results-beats-estimates-by-0-02-eps.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.